Moore Capital Management LP Buys 35,026 Shares of Elevance Health, Inc. $ELV

Posted by Francis Steltz on Jun 18th, 2026

Moore Capital Management LP lifted its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 116.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 65,000 shares of the company’s stock after buying an additional 35,026 shares during the period. Moore Capital Management LP’s holdings in Elevance Health were worth $22,786,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ELV. Rossby Financial LCC lifted its stake in Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. Kemnay Advisory Services Inc. bought a new position in Elevance Health during the fourth quarter worth about $31,000. J.Safra Asset Management Corp bought a new position in Elevance Health during the fourth quarter worth about $32,000. ORG Partners LLC lifted its stake in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Elevance Health during the fourth quarter worth about $38,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

NYSE:ELV opened at $392.04 on Thursday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The firm has a 50 day moving average of $372.34 and a 200-day moving average of $346.21. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $85.13 billion, a P/E ratio of 16.68, a price-to-earnings-growth ratio of 2.25 and a beta of 0.67.

Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the company posted $11.97 earnings per share. Elevance Health’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ELV shares. JPMorgan Chase & Co. raised their price target on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. The Goldman Sachs Group raised their price target on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Guggenheim raised their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Jefferies Financial Group cut their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Finally, Evercore restated a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $416.11.

Get Our Latest Stock Report on ELV

Insider Activity at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.34% of the company’s stock.

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.